Akkermansia muciniphila (pasteurized postbiotic)
Pasteurized Akkermansia muciniphila · also known as AKK bacteria, Akkermansia muciniphila, Pasteurized AKK
In mouse studies, pasteurized Akkermansia (a postbiotic) can improve markers of the mucus barrier and tight junctions. Direct human evidence is still limited, and an improvement in glucose and lipid metabolism or in the intestinal barrier cannot yet be confirmed.
Clinical uses and human evidence
Blood sugar and insulin resistance
Studies (2)
- Suenaert 2026 · Gut Microbes · RCT · n=142 — Effect of pasteurized Akkermansia muciniphila MucT on insulin sensitivity, body composition, and GLP-1 production in subjects with metabolic syndrome: impact of low baseline gut Akkermansia levels
- Depommier 2019 · Nat Med · RCT · n=40 — Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study
Body weight and body fat
Studies (2)
- Mount 2026 · Nat Med · RCT · n=90 — Pasteurized Akkermansia muciniphila Muc(T) for weight loss maintenance in people with overweight and obesity: a controlled randomized trial
- Depommier 2019 · Nat Med · RCT · n=40 — Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study
Muscle strength and mass
Polycystic ovary syndrome
Mechanisms of action
Secretion of intestinal mucin (MUC2) and the protective mucus gel layer
In a mouse antibiotic-associated diarrhea model, pasteurized bacteria improved barrier markers such as Muc2. Cell experiments show that Amuc_1100 can activate TLR2, but the full chain from TLR2 to MUC2 secretion and then to a thicker mucus layer in humans has not been confirmed.
Epithelial tight junction (ZO-1 / Occludin) reinforcement and barrier repair
In animal studies, inactivated bacteria can upregulate tight-junction proteins such as ZO-1 and occludin and limit their downregulation. In humans, changes in blood endotoxin or metabolic markers cannot prove that tight-junction proteins are upregulated, nor do they show that bacterial products entering the blood are fully blocked.
AMPK sensing of cellular energy deficit and metabolic reprogramming
AMPK-related changes come from mouse and cell experiments. For example, GLP-1 and AMPK-related markers changed in a study of a specific inactivated strain. But no reliable human study has measured tissue AMPK activation after oral intake of inactivated bacteria, and a causal link between GLP-1 and liver AMPK has not been established.
Pattern recognition receptor (PRR) immune surveillance and trained immunity
Amuc_1100 can activate TLR2 in cells. In mouse studies, loss of TLR2 partly cancels the effect of purified Amuc_1100. But this evidence comes from a purified protein and cannot directly show that whole inactivated bacteria have the same immune effect in humans.